

CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET

Product name Crry, Rat, clone TLD-1C11, FITC conjugated

Catalog number	HM3032F		
Lot number	-	Expiry date	-
Volume	1 ml	Amount	100 µg
Formulation	0.2 µm filtered in PBS+1%BSA+0.02%NaN3	Concentration	100 µg/ml
Host Species	Mouse IgG1	Conjugate	FITC
Endotoxin	N.A.	Purification	Protein G
Storage	4°C		

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #								
Yes	•		•	•	•	•		٠
No								
N.D.		•					•	

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

General Information

Description	The monoclonal antibody TLD-1C11 reacts with rat-complement regulator Crry. Complement comprises a system soluble serum proteins that, upon activiation by antibody (classical pathway), sugars (lectin pathway), or bacterial a foreign surfaces (alternative pathway), directly causes cell damage. Complement is constantly activated at low lew in serum, requiring cells to be protect themselves from damage. In human, cells are protected from compleme mediated damage by expression of membrane-bound complement regulatory proteins, which act at serveral por along the cascade. Human cells are protected by decay-accelerating factor (DAF, CD55), membrane cofactor pror (MCP, CD46) and membrane attack complex inhibitor protein 1 (MIN1, CD59). Furthermore the rat analogues of D MCP and CD59 have been characterized. Rats and mice express a unique membrane complement regulator of activating pathways, called complement receptor type-1 related gene Y (Crry). In rats there are two isoforms of C with six or seven short consensus repeats (SCR), encoding 65-70 and 75-85 kDa proteins, respectively, which both transmembrane anchored. Although Crry has the functional properties of both DAF and MCP, it does not repl. them. All rat blood cells express Crry whereas approximately 37 and 39% of the rat T cells express respectively and CD59. Studies in rat revealed that despite lacking DAF and CD59, these double-negative rat T cells were not m susceptible to homologous complement regulator, Crry, enhanced lysis only at the double-negative cells. In rats, Crry expowerful control in the activation pathways where it acts both as a cofactor and as a decay accelerator to inactiv convertases. Crry has been succesfully expressed and refolded in bacteria. The refolded protein has full-complemer regulatory activity in vitro, and has been applied in rat models of arthritis and other inflammatory diseases.					
Immunogen	Rat microglial cells					
Aliases	p65, complement receptor type-1 related gene Y, Complement regulator Crry					
References	 Flaris, N et al; Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia 1993, 7: 34 McGrath, Y et al; Development of adenovirus vectors encoding rat complement regulators for use in therapy in rodent models of inflammatory diseases. J Immunol 1999, <i>163</i>: 6834 Fraser, D et al; Bacterial expression and membrane targeting of the rat complement regulator Crry: a new mode anticomplement therapeutic. Protein Sci 2002, <i>11</i>: 2512 Hanna, S et al; Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement. Eur J Immunol 2002, <i>32</i>: 502 					
Storage&stability	Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.					
www.hycultbiotech.com	All Hycult Biotech products are subject to strict quality control procedures. Version: 02-2018 Copyright® Hycult Biotech. All rights reserved.					

Precautions

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC Robbert Zwinkels

Date 16/03/2018

Do you have any questions or comments regarding this product? Please contact us via support@hycultbiotech.com.